title: Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis.
abstract: Two hundred and ninety-six patients were enrolled in a 6-month, open-label tolerability study of enteric-coated naproxen in patients with rheumatoid arthritis (n = 174) and osteoarthritis (n = 122). Thirty percent of the patients were greater than 65 years of age. Under standard clinical prescribing conditions, enteric-coated naproxen 500 mg twice daily and 375 mg twice daily demonstrated an acceptable tolerability profile that was not different from what one would expect with standard naproxen.
authors.affiliation: Department of Medicine, University of Western Ontario, London, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Bellamy
authors.forename: A
authors.initials: A
authors.lastname: Beaulieu
authors.forename: C
authors.initials: C
authors.lastname: Bombardier
authors.forename: J
authors.initials: J
authors.lastname: Esdaile
authors.forename: S
authors.initials: S
authors.lastname: Huang
authors.forename: A V
authors.initials: AV
authors.lastname: Jovaisas
authors.forename: V N
authors.initials: VN
authors.lastname: Khanna
authors.forename: G
authors.initials: G
authors.lastname: Kraag
authors.forename: D M
authors.initials: DM
authors.lastname: Mehta
authors.forename: H A
authors.initials: HA
authors.lastname: Ménard
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D013608:Tablets, Enteric-Coated
chemical_list: D013608:Tablets, Enteric-Coated; D009288:Naproxen